Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Reporting soon: earnings call Wednesday, Oct 21
A pre-earnings brief is ready for ABT: the setup, what peers and partners said this season, and which analysts to watch.Reading it is a Tellvest Pro feature.
Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
| Analyst | Firm | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Robbie Marcus | JPMorgan | 8 questions · 13% challenging |
| Travis Steed | Bank of America | 7 questions · 0% challenging |
| Larry Biegelsen | Wells Fargo | 7 questions · 14% challenging |
| Josh Jennings | TD Cowen | 7 questions · 0% challenging |
| Vijay Kumar | Evercore ISI | 7 questions · 0% challenging |
| David Roman | Goldman Sachs | 6 questions · 0% challenging |
| Joanne Wuensch | Citigroup | 6 questions · 0% challenging |
| Danielle Antalffy | UBS | 4 questions · 0% challenging |
| Marie Thibault | BTIG | 4 questions · 0% challenging |
| Matt Taylor | Jefferies | 3 questions · 0% challenging |
| Firm | Analysts | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| JPMorgan | 1 analyst | 8 questions · 13% challenging |
| Bank of America | 1 analyst | 7 questions · 0% challenging |
| Evercore ISI | 1 analyst | 7 questions · 0% challenging |
| TD Cowen | 1 analyst | 7 questions · 0% challenging |
| Wells Fargo | 1 analyst | 7 questions · 14% challenging |
| Goldman Sachs | 1 analyst | 6 questions · 0% challenging |
| Citigroup | 1 analyst | 6 questions · 0% challenging |
| BTIG | 1 analyst | 4 questions · 0% challenging |
No 8-K events recorded for this window.
Abbott grew 3.7% on a comparable basis with adjusted EPS of $1.15 up 6%, as the Exact Sciences acquisition added a cancer diagnostics platform while the EP franchise accelerated with dual PFA catheter launches. CGM growth moderated to 7.5% on tender delays and tough comparisons, though the underlying adoption trajectory remained intact. Management set a new guidance range with $5.48 EPS at the midpoint incorporating $0.20 of Exact Sciences dilution, while the Nutrition pricing reset began driving volume recovery.
Product Launch | Revenue Growth | Competitive Dynamics | Demand | Innovation & R&D | Guidance Reliability | M&A | Regulation Policy | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 3 | 3 | 2 | 2 | 2 | 1 | 1 | |
| 2025Q1 | 3 | 2 | 3 | 2 | 1 | 1 | ||
| 2025Q2 | 5 | 2 | 2 | 1 | 1 | 2 | 2 | 2 |
| 2025Q3 | 5 | 3 | 4 | 2 | 1 | 1 | 1 | |
| 2025Q4 | 4 | 1 | 4 | 1 | 2 | 1 | 1 | |
| 2026Q1 | 2 | 3 | 3 | 2 | 2 | 1 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Product Launch | 3 | 3 | 5 | 5 | 4 | 2 |
| Revenue Growth | 3 | 2 | 2 | 3 | 3 | |
| Competitive Dynamics | 2 | 2 | 4 | 1 | 3 | |
| Demand | 2 | 1 | 2 | 4 | 2 | |
| Innovation & R&D | 2 | 3 | 1 | 1 | 1 | 2 |
| Guidance Reliability | 2 | 2 | 1 | 2 | 1 | |
| M&A | 1 | 1 | 2 | 1 | 1 | |
| Regulation Policy | 1 | 1 | 2 | 1 | 1 |
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $10.97B | +7.2% | $5.27 | +479.1% | 51.0% | 18.1% | 84.1% | $2.15B |
| FY2025 Q1 | $10.36B | +4.0% | $0.76 | +8.3% | 52.6% | 16.3% | 12.8% | $933M |
| FY2025 Q2 | $11.14B | +7.4% | $1.01 | +36.5% | 56.4% | 18.4% | 16.0% | $1.54B |
| FY2025 Q3 | $11.37B | +6.9% | $0.94 | 0.0% | 55.7% | 18.1% | 14.5% | $2.29B |
| FY2025 Q4 | $11.46B | +4.4% | $1.02 | -80.6% | 57.0% | 19.6% | 15.5% | $2.63B |
| FY2026 Q1Selected | $11.16B | +7.8% | $0.62 | -18.2% | 56.3% | 16.5% | 9.6% | $916M |
| FY2026 Q2 | $12.59B | +13.0% | $0.53 | -47.5% | 58.0% | 14.2% | 7.4% | $2.89B |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
Calendar quarter Q1 2026Earnings call Apr 16, 2026
FY2026 Q1 in brief
Abbott grew 3.7% on a comparable basis with adjusted EPS of $1.15 up 6%, as the Exact Sciences acquisition added a cancer diagnostics platform while the EP franchise accelerated with dual PFA catheter launches.
Newest quarter FY2026 Q2 is part of Pro · see what Pro adds →
GAAP revenue YoY +7.78% → base 6. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
Sources. Tellvest earnings-call sentiment score for Abbott Laboratories (ABT), FY2026 Q1: 6/10. Scores: Abbott Laboratories’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: ABT daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
What ABT and other companies said about each other on FY2026 Q1 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“Medtronic continues to be a solid competitor, J&J is enhancing their footprint in PFA and Abbott is early stages of launch in the U.S.”
BSX flags Abbott as an early-stage U.S. entrant in PFA, adding to the four-player competitive set pressuring BSX's EP outlook.
“It's really about being first in line to integrate day 1 with sensors like we're doing with the Dexcom 15 day, and we will do with Abbott's upcoming dual analyte sensor.”
Insulet plans day-one integration with Abbott's upcoming dual-analyte sensor, supporting Abbott's diabetes-care sensor franchise via the Omnipod platform.
“This quarter also marked an important strategic milestone for Abbott Laboratories with the completion of our acquisition of Exact Sciences.”
Abbott completed its acquisition of cancer-diagnostics company Exact Sciences (~$3B incremental 2026 sales), entering cancer diagnostics via Cologuard.
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
ABT Abbott Laboratories | 6 | +7.8% | |
| ALGN Align Technology | 6 | +6.2% | |
| BSX Boston Scientific | 6 | +11.6% | |
| DXCM DexCom | 9 | +15.1% | |
| EW Edwards Lifesciences | 9 | +16.7% | |
| MDT Medtronic | 7 | +8.8% | |
| PODD Insulet Corporation | 8 | +33.9% | |
| STE Steris | 7 | +7.3% | |
| SYK Stryker Corporation | 4 | +2.6% | |
| ZBH Zimmer Biomet | 9 | +9.3% |